华东医药2025年第三季度报告（英文版）

The 2025 Third Quarterly Report of Huadong Medicine Co., Ltd.1Security code: 000963Stock abbreviation: Huadong MedicineAnnouncement No.: 2025-098Huadong Medicine Co., Ltd.Third Quarterly Report 2025The Company and all members of the Board of Directors hereby guarantee that theinformation presented in this report is authentic, accurate and complete and free of any falserecords, misleading statements or material omissions.Important Declaration:1. The Board of Directors, directors and senior managers of Huadong Medicine Co., Ltd. (hereinafter referred toas the "Company") hereby guarantee that the information presented in the Report is authentic, accurate andcomplete and free of false records, misleading statements or material omissions, and shall undertake individualand joint legal liabilities.2. The Company's legal representative, the officer in charge of accounting, and the head of accountingdepartment (accounting supervisor) hereby declare that the financial information in this quarterly report isauthentic, accurate and complete.3. Has the Third Quarterly Financial Accounting Report been audited?□Yes NoAccording to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chineseand other language version of public notice, they should ensure the content of both versions are the same. In thecase of discrepancy, the original version in Chinese shall prevail.The 2025 Third Quarterly Report of Huadong Medicine Co., Ltd.2I. Key Financial Data(I) Key accounting data and financial indicatorsDoes the Company need to retroactively adjust or restate the accounting data of previous years?□Yes NoCurrent reportingperiodIncrease or decreaseduring the currentreporting periodcompared with thesame period of lastyearBeginning of the year tothe end of the reportingperiodChange from thebeginning of the year tothe end of the reportingperiod over the end oflast yearOperating revenue(RMB)10,989,214,170.474.53%32,664,143,135.683.77%Net profit attributableto shareholders of thelisted company (RMB)933,089,158.257.71%2,747,916,019.117.24%Net profit attributableto shareholders of thelisted company afterdeduction of non-recurring gains andlosses (RMB)931,780,891.878.77%2,693,515,147.858.53%Net cash flow fromoperating activities(RMB)——2,610,851,944.184.17%Basic earnings pershare (RMB/share)0.53898.45%1.56827.09%Diluted earnings pershare (RMB/share)0.53207.41%1.56667.02%Weighted averagereturn on equity3.79%-0.11%11.39%-0.31%End of the currentreporting periodEnd of the last yearIncrease or decrease at the end of the current reportingperiod compared with the end of the last yearTotal assets (RMB)39,928,783,200.4837,879,046,367.155.41%Owners' equityattributable toshareholders of listedcompanies (RMB)24,132,887,034.3123,060,051,397.364.65%(II) Non-recurring profit and loss items and amountsApplicable □Not applicableUnit: RMBItemAmount during the currentreporting periodAmount from the beginningof the year to the end of thereporting periodDescriptionGain